AN2 Therapeutics (ANTX) Cash from Investing Activities (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Cash from Investing Activities for 6 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 9.82% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $27.4 million (down 26.9% YoY), while the FY2025 annual figure was $28.3 million, down 48.14% from the prior year.
• Cash from Investing Activities improved to $8.3 million in Q1 2026 per ANTX's latest filing, from $7.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $26.3 million in Q1 2024 and bottomed at -$62.5 million in Q3 2023.
• Historically, Cash from Investing Activities has averaged $1.5 million across 5 years, with a median of $7.2 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 2595.81% — and 2025, when it jumped 204.27%.
• AN2 Therapeutics' Cash from Investing Activities stood at $6.1 million in 2022, then sank by 93.06% to $420000.0 in 2023, then slumped by 1738.1% to -$6.9 million in 2024, then surged by 204.27% to $7.2 million in 2025, then climbed by 15.56% to $8.3 million in 2026.
• Business Quant data shows ANTX's Cash from Investing Activities at $8.3 million in Q1 2026, $7.2 million in Q4 2025, and $6.1 million in Q3 2025.